Revenue: As of FY2026 Q2, the actual value is USD 153.6 M, beating the estimate of USD 151.81 M.

EPS: As of FY2026 Q2, the actual value is USD 0.18.

EBIT: As of FY2026 Q2, the actual value is USD 9.426 M.

Overall Performance

AtriCure, Inc. reported a net income of $9.0 million for the second quarter of 2026. Adjusted EBITDA for the quarter was $27.3 million. Cash generation amounted to $21.6 million for the second quarter of 2026.

Segment Revenue

Total United States Revenue for the second quarter of 2026 was $125.6 million, an increase of 13.6% from $110.6 million in 2025. Open ablation revenue in the U.S. was $40.9 million in 2026, compared to $36.5 million in 2025. Minimally invasive ablation revenue in the U.S. was $6.0 million in 2026, down from $7.8 million in 2025. Pain management revenue in the U.S. was $27.1 million in 2026, up from $21.2 million in 2025. Appendage management revenue in the U.S. was $51.6 million in 2026, compared to $45.1 million in 2025.

Total International Revenue for the second quarter of 2026 was $28.0 million, representing a 9.6% increase from $25.6 million in 2025, or 7.1% on a constant currency basis. Open ablation revenue internationally was $11.2 million in 2026, compared to $10.3 million in 2025. Minimally invasive ablation revenue internationally was $2.0 million in 2026, down from $2.4 million in 2025. Pain management revenue internationally was $2.4 million in 2026, up from $2.0 million in 2025. Appendage management revenue internationally was $12.4 million in 2026, compared to $10.8 million in 2025.

Profitability

Gross profit for the second quarter of 2026 was $118.6 million, compared to $101.5 million for the same period in 2025. Gross margin increased by 269 basis points to 77.2% for Q2 2026, compared to Q2 2025. Income from operations was $9.7 million for Q2 2026, a significant improvement from a loss of -$6.2 million for Q2 2025. Net income for Q2 2026 was $9.0 million, compared to a net loss of -$6.2 million for Q2 2025. Adjusted EBITDA for Q2 2026 was $27.3 million, an increase of $11.9 million or 78% from Q2 2025.

Operating Expenses

Cost of revenue was $35.0 million in 2026, compared to $34.7 million in 2025. Research and development expenses decreased to $26.4 million in 2026 from $29.3 million in 2025. Selling, general and administrative expenses were $82.6 million in 2026, up from $78.4 million in 2025. Total operating expenses for Q2 2026 were $109.0 million, compared to $107.7 million in Q2 2025.

Cash and Cash Equivalents

Cash and cash equivalents totaled $167.8 million as of June 30, 2026, a slight increase from $167.4 million as of December 31, 2025.

Outlook / Guidance

AtriCure, Inc. projects full year 2026 revenue to be approximately $602 million to $610 million. The company expects full year 2026 adjusted EBITDA to be approximately $85 million to $89 million. Additionally, AtriCure, Inc. anticipates continued positive cash generation for 2026.